How can pharmaceutical and biotechnology companies maintain a high profitability?

Author： Nickisch Klaus J   Greuel Joachim M   Bode-Greuel Kerstin M  

Publisher： Palgrave Macmillan Ltd

ISSN： 1478-565X

Source： Journal of Commercial Biotechnology, Vol.15, Iss.4, 2009-10, pp. : 309-323

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

How biotechnology companies respond to bioethical issues

By Kato M  

Journal of Commercial Biotechnology, Vol. 9, Iss. 2, 2003-01 ,pp. : 153-162

Palgrave Macmillan Ltd

Access to resources Recommend Favorite

Changes to the European Union pharmaceutical legislation: Implications of the ‘Pharma Review’ for biotechnology companies

By Liikanen Erkki  

Journal of Commercial Biotechnology, Vol. 11, Iss. 1, 2004-10 ,pp. : 38-43

Palgrave Macmillan Ltd

Access to resources Recommend Favorite

Sustainable development: how can biotechnology contribute?

By Zechendorf B.  

Trends in Biotechnology, Vol. 17, Iss. 6, 1999-06 ,pp. : 219-225

Elsevier

Access to resources Recommend Favorite

New technologies for neglected diseases: Can tax credits help biotechnology companies advance global health?

By Rao Aarthi  

Journal of Commercial Biotechnology, Vol. 17, Iss. 4, 2011-11 ,pp. : 290-292

Palgrave Macmillan Ltd

Access to resources Recommend Favorite

Bioethical concerns in Japanese biotechnology companies

By Kato Makina  

Journal of Commercial Biotechnology, Vol. 12, Iss. 3, 2006-04 ,pp. : 205-212

Palgrave Macmillan Ltd

Access to resources Recommend Favorite